Family presence when a child is undergoing tracheal intubation in a pediatric intensive care unit (PICU) can safely be implemented as part of a family-centered care model, reported a research team led by a University of Arkansas for Medical Sciences (UAMS) professor in the March 7 issue of JAMA Pediatrics.
Researchers from the University of Arkansas for Medical Sciences (UAMS) and other institutions are reporting the discovery of the first broad spectrum drug that can potently kill senescent (or aging) cells in culture and effectively clear the cells in animals by specifically targeting a pathway that is critical for the survival of senescent cells.
The University of Arkansas for Medical Sciences (UAMS) has become home to The Cancer Imaging Archive of the National Cancer Institute (NCI) with the transfer to UAMS of more than 40 terabytes of data from the archive’s former home at Washington University in St. Louis.
New findings on juvenile myelomonocytic leukemia (JMML) by researchers at the University of Arkansas for Medical Sciences (UAMS) and collaborators at other institutions were published online Oct. 12 by the medical journal Nature Genetics.
Identifying a patient’s genetic mutation led University of Arkansas for Medical Sciences (UAMS) physician-researcher Ling Gao, M.D., Ph.D., to an existing drug that eliminated the patient’s stage IV Merkel-cell carcinoma. Gao’s findings, made in collaboration with two other UAMS researchers, were published today in The New England Journal of Medicine. Metastatic Merkel-cell carcinoma is often fatal and there is no effective treatment. Gao’s 86-year-old female patient was diagnosed in 2013 with stage IIIB Merkel-cell carcinoma of the right temple. She had surgery and received radiation therapy in May 2013 and additional surgery in July 2014. In November 2014, doctors confirmed that the cancer had metastasized.
University of Arkansas for Medical Sciences (UAMS) researcher Vladimir Zharov, Ph.D., D.Sc., was awarded a $1.7 million grant by the National Cancer Institute for clinical testing of a new technology called Theranostics, which is an integration of early diagnosis and treatment of melanoma.
The University of Arkansas for Medical Sciences (UAMS) Medical Center recently became the only Arkansas hospital to earn the 2015 Most Wired Award from the American Hospital Association Health Forum and the College of Healthcare Information Management Executives (CHIME).
The therapies are designed to reduce or prevent the euphoric rush that drug users crave by keeping methamphetamine in the bloodstream and out of the brain, where the drug exerts its most powerful effects.
University of Arkansas for Medical Sciences (UAMS) researcher Vladimir Zharov, Ph.D., D.Sc., recently was awarded a $1.5 million R01 grant by the National Institutes of Health to investigate his diagnostic concept — “In vivo reading written in blood” — with new stimuli-responsive nanoparticles circulating in blood.
University of Arkansas for Medical Sciences (UAMS) researcher Vladimir Zharov, Ph.D., D.Sc., recently was awarded a $1.5 million R01 grant by the National Institutes of Health to investigate his diagnostic concept — “In vivo reading written in blood” — with new stimuli-responsive nanoparticles circulating in blood.
An inexpensive, disposable external medical device created and developed by University of Arkansas for Medical Sciences (UAMS) and University of Arkansas at Little Rock (UALR) professors can now be bought and used by clinicians to monitor contractions in pregnant women. The tocodynamometer, marketed as Koala Toco, was approved in May by the Food and Drug Administration. Koala Toco, manufactured and marketed by Murray, Utah-based Clinical Innovations, is compatible and works with existing equipment like fetal heart rate monitors.
Angel Eye Camera Systems, a company established in 2013 with support from the University of Arkansas for Medical Sciences (UAMS) BioVentures, recently completed the installation of 79 camera systems in the neonatal intensive care units (NICU) at Texas Health Presbyterian Hospital Dallas, Texas Health Presbyterian Hospital Plano and at Texas Health Harris Methodist Hospital Fort Worth. Complete with audio, parents can see and talk to their baby anytime, day or night from their mobile phone or computer.
A surprise discovery that could lead to new treatments for herpes viruses that infect more than 90 percent of the world’s adult population has led to a $1.8 million grant to the University of Arkansas for Medical Sciences (UAMS) from the National Cancer Institute (NCI) at the National Institutes of Health (NIH).
World-renowned multiple myeloma researcher and clinician Gareth Morgan, M.D., Ph.D., today was named director of the University of Arkansas for Medical Sciences (UAMS) Myeloma Institute for Research and Therapy (MIRT).
Angel Eye Camera Systems LLC, a new company, recently licensed Angel Eye™ technology from University of Arkansas for Medical Sciences (UAMS) BioVentures, and received an important capital investment from a Nashville, Tenn., venture fund.
InterveXion Therapeutics LLC and the University of Arkansas for Medical Sciences (UAMS) have successfully completed dosing in the first human safety study of a medication to help methamphetamine users fight their addictions.
Melanoma skin cancer survivors are much more likely than the general population to have future new cases of invasive melanomas and other cancers, says a national study led by UAMS’ Appathurai Balamurugan, M.D., M.P.H.
The University of Arkansas for Medical Sciences (UAMS) announces the start of a Phase 1 clinical trial to study the safety of a novel vaccine to prevent the recurrence of breast cancer. UAMS has three research subjects enrolled in the Phase 1 clinical trial and plans on completing the trial sometime in 2012 after studying the safety of the vaccine in up to 18 research subjects. After the safety testing phase is completed, UAMS expects to conduct another clinical trial using the vaccine on up to 50 research subjects.
Celebrating the grand opening of the Cord Blood Bank of Arkansas at the University of Arkansas for Medical Sciences (UAMS) today, Brian and Jennifer Odle told how the use of cord blood gave their 18-month-old daughter a new lease on life.
A new model of care developed for patients at the Myeloma Institute for Research and Therapy at the University of Arkansas for Medical Sciences (UAMS) has led to improved patient experience, lower costs and better patient outcomes.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right